Metabolic patterns across core features in dementia with lewy bodies

Morbelli, Silvia; Chincarini, A.; Brendel, Matthias; Rominger, Axel; Bruffaerts, Rose; Vandenberghe, Rik; Kramberger, Milica G.; Trošt, Maja; Garibotto, Valentina; Nicastro, Nicolas; Frisoni, Giovanni B.; Lemstra, Afina W.; Zande, Jessica van der; Padovani, Alessandro; Padovani, Alessandro; García-Ptacek, Sara; Savitcheva, Irina; Ochoa-Figueroa, M.A.; Davidsson, Annette; Camacho, Valle; Peira, Enrico; Arnaldi, Dario; Bauckneht, Matteo; Pardini, Matteo; Sambuceti, Gianmario; Aarsland, Dag; Nobili, Flavio

doi:10.1002/ana.25453

Cited by 50 publications

(66 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be explained by various potentially confounding circumstances. Previous studies have suggested that CIS may be influenced by the severity of cognitive impairment [11,30], however, in line with a previous study [15], we did not find a relationship between CIS and MMSE. The implementation of the visual CIS scale in a routine practice is potentially valuable considering that visual features including cingulate hypometabolism seemed to be underreported and missed on the clinical interpretation of FDG-PET scans of patients with DLB [13].…”

Section: Discussionsupporting

confidence: 86%

A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease

Gjerum

Frederiksen

Henriksen

et al. 2020

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Valid diagnosis of dementia with Lewy bodies (DLB) is essential to establish appropriate treatment and care. However, the diagnostic accuracy is complicated by clinical and pathological overlap with Alzheimer's disease (AD). Cingulate island sign (CIS), defined as sparing of posterior cingulate cortex (PCC) relative to precuneus and cuneus on 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET), is included in the revised diagnostic DLB criteria. There are no guidelines for the visual grading of CIS, although visual rating is a fastapplicable method in a clinical setting. The objective was to develop a robust visual CIS scale and evaluate the performance in differentiating DLB with and without amyloid beta pathology (Aβ+/−), and AD. 18F-FDG-PET scans from 35 DLB patients, 36 AD patients, and 23 healthy controls were rated according to a visual CIS scale based on specific reading criteria. The visual CIS scale was validated against a quantitative CIS ratio derived from a region of interest analysis of PCC, precuneus, and cuneus. DLB patients had a significantly higher visual CIS score compared to AD patients, and controls. A cutoff visual CIS score of 4 significantly differentiated DLB Aβ− patients from DLB Aβ+ patients. In conclusion, the visual CIS scale is clinically useful to differentiate DLB from AD. The degree of CIS may be related to Aβ pathology in DLB patients.

show abstract

Section: Discussionsupporting

confidence: 86%

A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease

Gjerum

Frederiksen

Henriksen

et al. 2020

Journal of the Neurological Sciences

View full text Add to dashboard Cite

show abstract

“…Subjects presenting with a normal 18 F-FDG-PET scan or an anterior pattern of hypo-metabolism were considered not to be eligible, while all subjects presented with a posterior pattern of hypo-metabolism felt to be possibly affected with AD or DLB. Details on the 18 F-FDG-PET acquisition were reported elsewhere [11]. To be included in the study, subjects needed to present clearly positive or negative 123 I-FP-CIT-SPECT scan (i.e., evidence of nigrostriatal degeneration for all DLB subjects and for none of the AD subjects based on normative data [12]) performed no later than 6 months after the first access to our centre and to have a clinical follow-up of at least 3 years after the 123 I-FP-CIT-SPECT scan confirming the baseline clinical diagnosis.…”

Section: Dlb and Ad Patientsmentioning

confidence: 99%

“…Putaminal 123 I-FP-CIT SPECT SBR values were 1.300 ± 0.410 and 1.260 ± 0.310 for the left and right putamen in the DLB group and 3.300 ± 0.890 and 3.000 ± 0.610 for the AD group. As per protocol, all DLB subjects and none of the AD subjects presented with 123 I-FP-CIT SPECT SBR values suggestive of NP degeneration based on multicentre normative data [11]. Focusing on the DLB group, there was a significant inverse correlation between 123 I-FP-CIT SPECT putamen SBR values and NP FA values (left, r = -0.670, p = 0.003; right, r = -0.720, p = 0.001; Fig.…”

Section: Correlation Between Np Diffusion Metrics and 123 I-fp-cit Spmentioning

confidence: 99%

123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Assessment of nigrostriatal degeneration is a key element to discriminate between dementia with Lewy bodies (DLB) and Alzheimer disease (AD), and it is often evaluated using ioflupane (123 I-FP-CIT) single-photon emission computed tomography (SPECT). Given the limited availability of 123 I-FP-CIT SPECT, we evaluated if a maskbased approach to nigroputaminal magnetic resonance imaging (MRI) diffusion-weighted tractography could be able to capture microstructural changes reflecting nigroputaminal degeneration in DLB. Methods: A nigroputaminal bundle mask was delineated on 12 healthy volunteers (HV) and applied to MRI diffusion-weighted data of 18 subjects with DLB, 21 subjects with AD and another group of 12 HV. The correlation between nigroputaminal fractional anisotropy (FA) values and 123 I-FP-CIT SPECT findings was investigated. Shapiro-Wilk, ANOVA, ANCOVA, and parametric correlation statistics as well as receiver operating characteristic (ROC) analysis were used. Results: DLB patients showed a higher nigroputaminal FA values compared with both AD and HV-controls groups (p = 0.001 for both comparisons), while no difference was observed between HV-controls and AD groups (p = 0.450); at ROC analysis, the area under the curve for the discriminating DLB and AD subjects was 0.820; FA values correlated with 123 I-FP-CIT values (on the left, r =-0.670; on the right, r =-720). No significant differences were observed for the FA of the corticospinal tract across the three groups (p = 0.740). Conclusions: In DLB, nigroputaminal degeneration could be reliably assessed on MRI diffusion scans using a mask of nigroputaminal bundle trajectory. Nigroputaminal FA in DLB patients correlated with 123 I-FP-CIT values data may allow to differentiate these patients from AD patients and HV-controls.

show abstract

“…A recent multi-center 18 F-FDG PET study explored regional correlates for the core symptoms in DLB. 46…”

Section: Diagnostic Clinical Correlates and Predictive Aspect Of mentioning

confidence: 99%

Functional neuroimaging evidence supporting the dual syndrome hypothesis of cognitive impairment in Lewy body disease

Hirano

2020

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

Parkinson's disease (PD) is a neurodegenerative disease that is characterized by progressive neuronal loss in the nigrostriatal dopaminergic system and the existence of Lewy bodies in the cytoplasm of the affected neurons. Dementia occurs in 10% to 30% of PD patients, and the risk increases with aging. 1 A wide range of cognitive domains may be affected in PD, including attention and working memory, executive function, language, memory, and visuospatial function. 2 Dementia of PD has several hypothetical pathological factors, which may overlap: (a) insufficiency of neurotransmitters in the dopaminergic, cholinergic, serotonergic, and noradrenergic systems; (b) the distribution of Lewy body and Alzheimer's disease (AD) pathology; (c) pharmacological adverse effects; (d) cerebral ischemia. Each factor may bear a specific expression for a dementia symptom.

show abstract

Metabolic patterns across core features in dementia with lewy bodies

Cited by 50 publications

References 52 publications

A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease

A visual rating scale for cingulate island sign on 18F-FDG-PET to differentiate dementia with Lewy bodies and Alzheimer's disease

123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies

Functional neuroimaging evidence supporting the dual syndrome hypothesis of cognitive impairment in Lewy body disease

Contact Info

Product

Resources

About